Clinical pharmacology of antidepressant drugs: pharmacogenetics
- PMID: 6380229
Clinical pharmacology of antidepressant drugs: pharmacogenetics
Abstract
There are marked interindividual differences in Css of tricyclic antidepressants. These are due mainly to corresponding differences in the rate of elimination of the drugs and hence in drug oxidation. Twin, family, and cross-over studies with NT and DMI show that their kinetics (Css, Kel, and Vd) are controlled mainly by genetic factors (in drug-free individuals). Slow hydroxylators are at risk of developing excessive plasma concentrations of NT and DMI when given per se or when formed from the tertiary amines AT and imipramine. Classic antidepressants have fairly well established concentration-effect curves in endogenous depression. Severe toxicity usually occurs at supratherapeutic plasma levels and might be prevented by tailoring the dosage according to the individual's drug hydroxylating capacity. Monitoring drug plasma levels is particularly relevant in slow hydroxylators. There is a strong association between an individual's ability to hydroxylate NT and DMI and his D hydroxylation phenotype. The ratios between D and 4-OH-D in urine after a single oral dose are bimodally distributed in the population (polymorphism), with 3 to 10% being slow hydroxylators and the remainder rapid hydroxylators. Indices of NT-hydroxylation do not sharply distinguish the two phenotypes. The D metabolic index will predict the patient's capacity to hydroxylate NT and DMI and hence Css during therapy. Possibly similar hydroxylases are involved in the 4-hydroxylation of debrisoquine, in the stereospecific E-10-hydroxylation of NT, and in the 2-hydroxylation of DMI. By contrast demethylation of AT (and probably other tertiary tricyclics) does not significantly correlate to debrisoquine hydroxylation. The increasing knowledge of the clinical pharmacokinetics of tricyclic antidepressants is a distinct advantage over that of the new generation of antidepressants, where little is known about concentration-effect relationships and factors governing their rate of metabolism.
Similar articles
-
Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.Prog Clin Biol Res. 1986;214:169-88. Prog Clin Biol Res. 1986. PMID: 3523507 Review.
-
Plasma level monitoring of antidepressants: theoretical basis and clinical application.Adv Biochem Psychopharmacol. 1984;39:399-411. Adv Biochem Psychopharmacol. 1984. PMID: 6380231 Review.
-
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].Encephale. 1996 May-Jun;22(3):221-7. Encephale. 1996. PMID: 8767051 French.
-
Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels.Pharmacopsychiatry. 2003 Jul;36(4):134-42. doi: 10.1055/s-2003-41198. Pharmacopsychiatry. 2003. PMID: 12905099 Clinical Trial.
-
The contribution of pharmacokinetics to the best use of benzodiazepines and antidepressants.Encephale. 1982;8(2):291-8. Encephale. 1982. PMID: 6125380
Cited by
-
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.Br J Clin Pharmacol. 2002 Feb;53(2):111-22. doi: 10.1046/j.0306-5251.2001.01548.x. Br J Clin Pharmacol. 2002. PMID: 11851634 Free PMC article. Review.
-
How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?Front Genet. 2020 Dec 8;11:491895. doi: 10.3389/fgene.2020.491895. eCollection 2020. Front Genet. 2020. PMID: 33363564 Free PMC article. Review.
-
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.Eur J Clin Pharmacol. 2010 Aug;66(8):755-74. doi: 10.1007/s00228-010-0857-7. Epub 2010 Jun 27. Eur J Clin Pharmacol. 2010. PMID: 20582584 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials